|
|
|
|
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis?
|
|
|
|
|
|
|
|
نویسنده
|
santoni m. ,conti a. ,procopio g. ,porta c. ,ibrahim t. ,barni s. ,guida f.m. ,fontana a. ,berruti a. ,berardi r. ,massari f. ,vincenzi b. ,ortega c. ,ottaviani d. ,carteni g. ,lanzetta g. ,de lisi d. ,silvestris n. ,satolli m.a. ,collovà e. ,russo a. ,badalamenti g. ,fedeli s.l. ,tanca f.m. ,adamo v. ,maiello e. ,sabbatini r. ,felici a. ,cinieri s. ,montironi r. ,bracarda s. ,tonini g. ,cascinu s. ,santini d.
|
|
منبع
|
journal of experimental and clinical cancer research - 2015 - دوره : 34 - شماره : 1
|
|
چکیده
|
Purpose: aim of this study was to investigate for the presence of existing prognostic factors in patients with bone metastases (bms) from rcc since bone represents an unfavorable site of metastasis for renal cell carcinoma (mrcc). materials and methods: data of patients with bms from rcc were retrospectively collected. age,sex,ecog-performance status (ps),mskcc group,tumor histology,presence of concomitant metastases to other sites,time from nephrectomy to bone metastases (ttbm,classified into three groups: <1 year,between 1 and 5 years and >5 years) and time from bms to skeletal-related event (sre) were included in the cox analysis to investigate their prognostic relevance. results: 470 patients were enrolled in this analysis. in 19 patients (4%),bone was the only metastatic site; 277 patients had concomitant metastases in other sites. median time to bms was 16 months (range 0 - 44y) with median os of 17 months. number of metastatic sites (including bone,p = 0.01),concomitant metastases,high fuhrman grade (p < 0.001) and non-clear cell histology (p = 0.013) were significantly associated with poor prognosis. patients with ttbm >5 years had longer os (22 months) compared to patients with ttbm <1 year (13 months) or between 1 and 5 years (19 months) from nephrectomy (p < 0.001),no difference was found between these two last groups (p = 0.18). at multivariate analysis,ecog-ps,mskcc group and concomitant lung or lymph node metastases were independent predictors of os in patients with bms. conclusions: our study suggest that age,ecog-ps,histology,mskcc score,ttbm and the presence of concomitant metastases should be considered in order to optimize the management of rcc patients with bms. © 2015 santoni et al.
|
|
کلیدواژه
|
Bone metastasis; Prognostic factors; Renal cell carcinoma; Time to distant metastasis
|
|
آدرس
|
department of medical oncology,aou ospedali riuniti,università politecnica delle,marche,ancona, Italy, department of clinical and specialist sciences,urology,università politecnica delle marche,ancona, Italy, department of medical oncology,fondazione irccs istituto nazionale dei tumori,milan, Italy, division of medical oncology,i.r.c.c.s. san matteo university hospital foundation,pavia, Italy, osteoncology and rare tumors center,irccs istituto scientifico romagnolo per lo studio e la cura dei tumori (irst),meldola,fc, Italy, medical oncology department,azienda ospedaliera treviglio-caravaggio,treviglio, Italy, department of medical oncology,campus bio-medico university of rome,rome, Italy, unit of medical oncology 2,istituto toscano tumori,azienda-ospedaliero-universitaria pisana,pisa, Italy, dipartimento di specialità medico-chirurgiche,medical oncology scienze radiologiche e sanità pubblica,università degli studi di brescia,brescia, Italy, department of medical oncology,aou ospedali riuniti,università politecnica delle,marche,ancona, Italy, department of medical oncology,g.b. rossi academic hospital,azienda ospedaliera universitaria integrata,verona, Italy, department of medical oncology,campus bio-medico university of rome,rome, Italy, department of medical oncology,institute for cancer research and treatment (ircc),candiolo,torino, Italy, department of medical oncology,presidio sanitario gradenigo,turin, Italy, department of medical oncology,cardarelli hospital,naples, Italy, department of neurological sciences,neuromed institute,ircss,pozzilli,is,italy,istituto neurotraumatologico italiano,unità funzionale di oncologia,grottaferrata, Italy, department of medical oncology,campus bio-medico university of rome,rome, Italy, medical oncology unit,national cancer research centre giovanni paolo ii,bari, Italy, department of oncology,university of turin,medical oncology 1,aou città della salute e della scienza,turin, Italy, division of medical oncology,hospital of legnano,milan, Italy, department of surgery and oncology,section of medical oncology,university of palermo,palermo, Italy, department of surgery and oncology,section of medical oncology,university of palermo,palermo, Italy, department of medical oncology,aou ospedali riuniti,università politecnica delle marche,presidio san salvatore,pesaro, Italy, department of medical oncology,university of cagliari,cagliari, Italy, department of human pathology,medical oncology unit aoor papardo-piemonte,university of messina,messina, Italy, oncology unit,irccs casa sollievo della sofferenza,san giovanni rotondo,fg, Italy, dipartimento integrato di oncologia ed ematologia,medical oncology division,università degli studi di modena e reggio emilia,modena, Italy, department of medical oncology,regina elena national cancer institute,rome, Italy, medical oncology department and breast unit,hospital of brindisi and medical oncology department,european institute of oncology,milan, Italy, section of pathological anatomy,polytechnic university of the marche region,school of medicine,ancona, Italy, department of oncology,usl-8,ospedale san donato,arezzo, Italy, department of medical oncology,campus bio-medico university of rome,rome, Italy, department of medical oncology,aou ospedali riuniti,università politecnica delle,marche,ancona, Italy, department of medical oncology,campus bio-medico university of rome,rome, Italy
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|